Open Menu
Meetings & Education
Meetings & Education
Research & Data
Practice & Patients
Career Development
News & Initiatives
Get Involved
Adaptive designed eniluracil + capecitabine phase 2 trial in advanced or metastatic breast cancer patients.
Background:
Ethynyl-uracil (eniluracil or 6422), an irreversible inhibitor of the dihydropyrimidine dehydrogenase enzyme that metabolizes 5-FU to catabolites, eliminates the formation of 5-FU catabolites and catabolite side effects while exposing cancer cells to more 5-FU and more cancer killing 5-FU anabolites. The combination of a single 40 mg day 1 dose of 6422 followed by Day 2 Capecitabine (6422+Cap) on a 7 day on + 7 day off schedule (7+7) of Capecitabine (Cap) is being evaluated. The dose of Cap used in 6422+Cap will be approximately 15% of the therapeutic dose of Cap used in clinical practice for breast cancer.
A Phase 1B study in patients with refractory gastrointestinal (GI) cancer has been completed. The Maximum Tolerated Dose of Cap in 6422+Cap was determined to be 225 mg BID. The Recommended Phase 2 Dose Range of Cap in 6422+Cap was determined to be from 75 mg BID to 225 mg BID. based on the FDA’s Optimal Design Guidance and Project Optimus initiative to define the dose-response relationship for both safety and efficacy.
Since FDA believed that determining the optimal dosage regimen following the Principles of Project Optimus would be extremely difficult for 6422+Cap in GI cancer given the standard combination chemotherapeutic treatments, the target population was changed to breast cancer patients. FDA also determined that a Phase 1B study in breast cancer would not be required given the GI cancer Phase 1B data.
Methods:
Several Project Optimus focused Phase 2 designs were evaluated. Based on guidance from the FDA, an adaptive, 3 arm, 30 patients/arm, phase 2, open-labelled, randomized trial was selected which would compare 2 regimens of 6422+Cap vs. standard dose of Cap alone. The study would initially enroll patients into 2 treatment arms. The 2 arms are: a 1000 mg/m2 BID monotherapy Cap control group and a 6422+Cap regimen of 40 mg on day 1 followed by day 2 Cap dose of 150 mg BID on 7+7 schedule. Upon completing the enrollment and evaluation of 9-10 patients in each of the first 2 arms, an interim analysis will be conducted to determine the Cap dose to be used in the 6422+Cap 3rd arm. Depending on the interim results, Cap dose in the 3rd arm will either be increased to 225 mg BID or decreased to 75 mg BID.
Patients with triple-negative or HR positive/HER2 negative, advanced or metastatic breast cancer are eligible for the study. Patients should have measurable disease in accordance with RECIST 1.1. Patients with stable brain metastases are eligible. The primary endpoint of the study is Objective Response Rate. This will be assessed based on the null hypothesis that the endpoint in each 6422+Cap arm is less than or equal to the monotherapy arm. Additionally, safety will be assessed by the incidence and severity of adverse events across treatment groups. The pharmacokinetics of Cap, 5-FU, and the FBAL catabolite will be evaluated using population PK analysis. Currently 3 patients have been enrolled in the study.
Disclaimer
This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Author Details
David Young
Processa Pharmaceuticals, Inc., Hanover, MD
Authors chevron_right
Associated Organizations chevron_right
Abstract Details
Meeting
2025 ASCO Annual Meeting
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
View MoreAbstract Disclosure
open_in_new
Download
Your Privacy
ASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us.
Because we respect your right to privacy, you can choose not to allow some or all types of cookies. Click on the different category headings to find out more about the types of cookies used on our websites and change your default settings to match your preferences. Please read these carefully. Blocking some types of cookies may impact your experience on the site, including our ability to personalize the content you receive from us.
For a full explanation of the personal and non-personal information we collect on our site, including how we use that information and your rights regarding that information, please review our Privacy Policy. Use of our website is also subject to our Terms of Use.
Allow All
Manage Consent Preferences
Essential Website Cookies
Always Active
These cookies are necessary for the website to function and are sometimes referred to as “strictly necessary” cookies. They make sure the website delivers you information and services in an optimal way.
They are often set in response to an action you take, such as changing your cookie preferences, setting your privacy preferences, logging in to our website, asking the site to remember you on subsequent pages, or filling in forms. These cookies do not identify you personally.
You can set your browser to block or alert you about all cookies, including essential website cookies, but some parts of the site will not work as a result.
Cookies Details‎
Performance and Functionality Cookies
Performance and Functionality Cookies
These cookies enhance the performance and functionality of our websites and the services we provide. For example, these cookies can keep track of your visitor session in between visits, enable you to share content through social media, use embedded media players, and use comment features. They also help us balance website load and improve site speed and performance.
All information these cookies collect is aggregated and therefore anonymous. These cookies may be set by us or by third party providers whose services we have added to our websites. These cookies are non-essential, but without these cookies, certain functionality or enhanced features may become unavailable.
Cookies Details‎
Personalization and Analytics Cookies
Personalization and Analytics Cookies
These cookies collect information that is used to help us understand how our websites and content are used, help us customize our websites and application for you in order to enhance your experience, and help us improve the content that ASCO creates to better meet our members’ and visitors’ needs. Examples include cookies that show us which content might be most popular with our visitors, understand browsing history of our users, understand the effectiveness of our own advertising, and enable us to recommend content to individual users based on their profile and activities on the website.
These cookies may be set by us or by third party providers whose services we have added to our websites.
These cookies are non-essential to the functionality of the site and may contain information that enables us or our third party providers to identify you and build a profile of your interests. Without these cookies, you will not be able to have a customized or personalized experience within our website.
Cookies Details‎
Advertising Cookies and Social Media Cookies
Advertising Cookies and Social Media Cookies
Advertising (or Targeting) cookies are third party cookies that may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant ads on other sites.
Social Media Cookies are cookies set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your activities across other sites and building a profile of your interests. This may impact the content and messages you see on other websites you visit.
These cookies and the data collected by the third parties may be combined with data from other users or data about your activity on other sites. While the data collected on our site is aggregate or non-personal, the data may be used by such third parties to link you on other platforms or otherwise identify you.
If you do not allow these cookies, you may experience less targeted advertising.
Cookies Details‎
Back Button
Cookie List
Search Icon
Filter Icon
Clear
checkbox labellabel
ApplyCancel
ConsentLeg.Interest
checkbox labellabel
checkbox labellabel
checkbox labellabel
View Cookies
Name
cookie name
Save Settings
iframeBrand%3B24.0.0.0&uamb=0&uam=&uap=Linux%20x86_64&uapv=6.6.72&uaw=0&fledge=1&data=event%3Dgtag.config)